Valdés-Solís E, Colorado-García LM, Lozano-Nuevo JJ, Rubio-Guerra F

Idioma: Español
Referencias bibliográficas: 48
Paginas: 190-200
Archivo PDF: 730.42 Kb.

RESUMEN

Antecedentes: con el mejor conocimiento de la patogenia de la psoriasis, ésta ha dejado de ser una enfermedad exclusivamente cutánea para pasar a ser una enfermedad inflamatoria crónica con manifestaciones sistémicas. Se han descrito numerosas comorbilidades asociadas con la psoriasis, entre ellas, mayor prevalencia de síndrome metabólico y factores de riesgo cardiovascular, artropatía, mayor consumo de tabaco y alcohol, manifestaciones psicológicas y alteración de la calidad de vida.
Objetivo: evaluar la asociación entre síndrome metabólico y psoriasis severa en placas.
Material y Método: estudio transversal, analítico, realizado en pacientes con psoriasis severa del Hospital General de Xoco. Se determinaron los datos demográficos y las características de la psoriasis en placas (tiempo de evolución, antecedentes familiares, gravedad y tratamiento), existencia de comorbilidades y su tratamiento (antecedentes de hipertensión arterial, diabetes, dislipidemia) índice cintura-cadera, índice de masa corporal, resultados analíticos (glucosa, colesterol, triglicéridos) y hábitos tóxicos (tabaco y alcohol).
Resultados: se incluyeron 132 pacientes (60% hombres y 40% mujeres) con edad entre 18 y 55 años. Encontramos una prevalencia elevada de sobrepeso y obesidad (73%) y criterios de síndrome metabólico en 37% de los pacientes, sin diferencia entre hombres y mujeres. Se encontró relación estadística entre el síndrome metabólico y la severidad de la psoriasis (p=0.001), el consumo de alcohol (p=0.001) y el tipo de tratamiento contra la psoriasis (p=0.001).
Conclusiones: encontramos una prevalencia alta de síndrome metabólico y de cada uno de sus componentes, especialmente de obesidad, con relación importante de ese síndrome con la gravedad y tratamiento de la psoriasis.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Gelfand JM, Yeung H. Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl 2012;89:24-28. doi:10.3899/jrheum.120237.

2. Bell LM, Sedlack R, Beard CM, Perry H, et al. Incidence of psoriasis in Rochester, Minn., 1980-1983. Arch Dermatol 1991;127:1184-1187.

3. Vena GA, Altomare G, Ayala F, Berardesca E, et al. Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database. Eur J Dermatol 2010;20:593-598.

4. Jurado SCF y col. Psoriasis y síndrome metabólico. Rev Cent Dermatol Pascua 2013;22.

5. Lebwohl M. Psoriasis. Lancet 2003;361:1197-1204.

6. Ferrándiz C, Pujol RM, García-Patos V, Bordas X, Smandía JA. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002;46:867-873.

7. Kaur I, Handa S, Kumar B. Natural history of psoriasis: a study form Indian subcontinent. J Dermatol 2007;24:230-234.

8. Andressen C, Henseler T. Inheritance of psoriasis. Analysis of 2035 family histories. Hautzarzt 2002;33:214-217.

9. Nair RP, Stuart PE, Nistor I, Hiremagalore R, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2008;78:827-851.

10. Trembath RC, Clough RL, Rosbotham JL, Jones AB, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 2009;6:813-820.

11. Mallon E, Newson R, Bunker CB. HLA-Cw6 and the genetic predisposition to psoriasis: a meta-analysis of published serologic studies. J Invest Dermatol 1999;113:693-695.

12. Duffy DL, Spelman LS, Martin NG. Psoriasis in Australian twins. J Am Acad Dermatol 1993;29:428-434.

13. Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B, Kristinsson KG, Valdimarsson H. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol 2003;149:530-534.

14. Leal L, Ribera M, Daudén E. Psoriasis e infección por el virus de la inmunodeficiencia humana. Actas Dermosifiliogr 2008;99:753-763.

15. Picardi A, Mazzotti E, Gaetano P, Cattaruzza MS, et al. Stress, social support, emocional regulation, and exacerbation of diffuse plaque psoriasis. Psychosomatics 2005;46:556-564.

16. Schmid-Ott G, Jaeger B, Boehm T, Langer K, et al. Immunological effects of stress in psoriasis. Br J Dermatol 2009;160:782-785.

17. Michaëlsson G, Gustafsson K, Hagforsen E. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol 2006;54:737-738.

18. Gerdes S, Zahl VA, Weichenthal M, Mrowietz U. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology 2010;220:38-43.

19. Daudén E, Castañeda S, Suárez C, García-Campayo J, et al. Integrated approach to comorbidity in patients with psoriasis. Working Group on Psoriasis-Associated Comorbidities. Actas Dermosifiliogr 2012;103:1-64.

20. Wolters M. Diet and psoriasis: experimental data and clinical evidence. Br J Dermatol 2005;153:706-714.

21. Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol 2010;49:1351-1361.

22. Morell L, Carrascosa JM, Ferrándiz C, García-Bustinduy M, et al. Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European medicines agency: a multicenter observational study. Actas Dermosifiliogr 2011;102:354-364.

23. Camargo CM, Brotas AM, Ramos-e-Silva M, Carneiro S. Isomorphic phenomenon of Koebner: facts and controversies. Clin Dermatol 2013;31:741-749.

24. Attwa E, Swelam E. Relationship between smokinginduced oxidative stress and the clinical severity of psoriasis. J Eur Acad Dermatol Venereol 2011;25:782-787.doi: 10.1111/j.1468-3083.2010.03860.x.

25. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009;129:1339-1350.

26. Ghoreschi K, Weigert C, Röcken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007;25:574- 580.

27. Nograles KE, Davidovici B, Krueger JG. New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg 2010;29:3-9.

28. Griffiths CE, Barker JN. Psoriasis 1: pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-271.

29. Cantini F, Niccoli L, Nannini C, Kaloudi O, et al. Psoriasis arthritis: a systematic review. Int J Rheum Dis 2010;13:300- 317.

30. Syed ZU, Khachemoune A. Inverse psoriasis: case presentation and review. Am J Clin Dermatol 2011;12:143-146.

31. Baran R. The burden of nail psoriasis: an introduction. Dermatology 2010;221:1-5.

32. Zeichner JA, Lebwohl MG, Menter A, Bagel J, et al. Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis 2010;86:5-31.

33. Fonseca E, Paradela S, Rodríguez Lozano J, Fernández Torres R. Guías para el tratamiento de la psoriasis en placas moderada-grave con terapias biológicas. En: Fonseca E. Terapias biológicas para la psoriasis. Madrid, 2009:117-136.

34. Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Ther 2010;23:114-118.

35. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013;8:4-6.

36. Pais R, Silaghi H, Silaghi AC, Rusu ML, Dumitrascu DL. Metabolic syndrome and risks of subsequent colorectal cancer. World J Gastroenterol 2009;15:5141-5148.

37. Arias-Santiago S, Orgaz-Molina J, Castellote-Caballero L, Arrabal-Polo MA, et al. Atheroma plaque, metabolic syndrome and inflammation in patients with psoriasis. Eur J Dermatol 2012;22:337-344.

38. Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol 2010;90:23-26.

39. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus. A systematic review and meta-analysis. Arch Dermatol 2012:1-8. doi: 10.1001/2013. jamadermatol.406.

40. Espinola-Klein C, Gori T, Blankenberg S, Munzel T. Inflammatory markers and cardiovascular risk in the metabolic syndrome. Front Biosci 2011;16:1663-1674.

41. Shibata S, Tada Y, Hau C, Tatsuta A, et al. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. Br J Dermatol 2011;164:667-670.

42. Mehta NN, Azfar RS, Shin DB, Neimann AL, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010;31:1000-1006.

43. Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based study in the United Kingdom. Arch Dermatol 2003;139:1425-1429.

44. Hayes J, Koo J. Psoriasis: depression, anxiety, smoking, and drinking habits. Dermatol Ther 2010;23:174-180.

45. Bronsard V, Paul C, Prey S, Puzenat E, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010;24:17-22.

46. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009;60(2):218- 224. doi: 10.1016/j

47. Ferrándiz C, Carrascosa JM, Boada A. A new era in the management of psoriasis? The biologics: facts and controversies. Clin Dermatol 2010;28:81-87. doi: 10.1016.

48. Mak RK, Hundhausen C, Nestle FO. Progress in understanding the immunopathogenesis of psoriasis. Actas Dermosifiliogr 2009;100:2-13. AVISO PARA LOS AUTORES